Valuation
- Market cap
- 2,597,268,000
- Revenue TTM
- $0
- Net income TTM
- $-86,970,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 581,500
- Avg volume
- 524,324
- Day's range
- $47.50 – $50.15
- Shares out
- 48,160,000
- Stochastic %K
- 33%
- Beta
- 0.10
- Analysts
- Strong Sell
- Price target
- $86.00
Company profile
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX...
Show more
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 317 659 0200
- Website
- https://mbxbio.com
- Address
- 11711 North Meridian Street, Suite 300, Carmel, United States
Latest news
No headlines yet.
